A B S T R A C T The effect of magnesium chloride or magnesium sulfate infusion on circulating levels of immunoreactive calcitonin (iCT) was evaluated on nine occasions in three patients with metastatic medullary carcinoma of the thyroid. One patient was normocalcemic and had normal circulating levels of immunoreactive parathyroid hormone (iPTH), one patient was hypocalcemic and had surgical hypoparathyroidism, and one patient had mild to moderate hypercalcemia associated with bone metastases. The basal serum iPTH levels were undetectable in the latter two patients. In every instance magnesium administration produced a rapid and striking fall in circulating iCT and usually a detectable fall in serum calcium. During the hypermagnesemic state, serum iPTH fell from normal to undetectable in the patient with normal parathyroid function, while serum iPTH levels remained undetectable in the hypoparathyroid patient and in the patient with hypercalcemia associated with bone metastases. The results of these studies indicate that: (a) contrary to what has been reported in normal experimental animals, magnesium administration lowers circulating iCT in human subjects with thyroid medullary carcinoma and (b) the calcium-lowering effect produced by magnesium in patients with medullary carcinoma may, in part at least, be due to a redistribution of body calcium that is not mediated by the actions of either parathyroid hormone or calcitonin.
INTRODUCTION
It has been well established that the secretion of calcitonin is under the control of the blood calcium level with hypercalcemia stimulating the release of this hormone from the thyroid gland. There are many similarities, both biological and chemical, between magnesium and calcium and the possibility that magnesium might influence calcitonin secretion has, therefore, been studied in experimental animals by several investigators. The reports of in vitro, in situ, and in vivo animal studies all indicate that magnesium, like calcium, stimulates the release of calcitonin from the thyroid gland (1) (2) (3) (4) . Moreover, on the basis of the results of the in vivo studies, it has been suggested that the characteristic hypocalcemic effect produced by magnesium administration is the result of magnesium-induced release of calcitonin.
In normal man, the serum concentration of calcitonin is low and, because of methodologic problems, difficult to quantify. Therefore, the secretion of calcitonin in human subjects has been most extensively studied in patients with medullary carcinoma of the thyroid, who characteristically have high circulating levels of the hormone. Similar to what has been observed in normal experimental animals, the administration of calcium increases the serum calcitonin concentration in these patients. However, there is little information concerning the possible interrelationship of magnesium and calcitonin in man. The purpose of the present investigation was to study the effect of magnesium administration on circulating levels of calcitonin in patients with medullary carcinoma of the thyroid. Much to our surprise and in direct contrast to the reported studies in normal laboratory animals, we found that experimentally-induced hypermagnesemia consistently produced a rapid and striking fall in the serum calcitonin concentration in these patients.
METHODS Laboratory methods
Serum and urine calcium and magnesium were determined by atomic absorption spectrophotometry (model 303 The It has been demonstrated that serum samples can produce nonspecific displacement of tracer from antibody in the calcitonin immunoassay procedure (7) . Therefore, to eliminate or minimize this artifact, calcitonin concenitration was determined in the serum samples before and after charcoal adsorption, according to the procedure described by Deftos (7) . In the serum samples obtained in this study the calculated iCT conlcentrationis wvere 2-18%o low-er after thle addition of charcoal. Quantitatively, the effect pro-(Iiced by the apparent interferinig sulbstanices on the immunoassay determinationi of calcitonin x-as relatively coInstant in variouis serumil samples obtained from ani-one patient.
With our immiiunioassay procedure the concenitrationi of serum iCT in normiial clildreni an(l a(dults ranges from undetectable in most subjects (< 0.1 ng/miil) to less than 0.2 ng/ml. The intraassay variation is less tllan 8% whlile the interassay variation is less thanl 157c. Sequential serum samples obtained in each of the study periods to be described were always analyzed in the same assay, thus eliminating the effect of interassay variation.
Paticent 1, a 64-yr-old (60-kg) white male librarian, had a total thyroidectomy and radical neck dissection 3 yr before the study. Histological studies revealed medullary carcinoma of the thyroid with cervical lymph node metastases.
In addition, there was evidence of liver and pulmonary metastases. Postoperatively he developed hypocalcemia and the diagnosis of surgical hypoparathyroidism was made. The serum iCT concentration on admission was 11.6 ng/ml. The serum magnesium level increased to a high of 6.4 mg/100 ml during the infusion and then declined slowly to a level of 3.8 mg/100 ml over the 17-h period following the discontinuation of the infusion. The serum iCT declined rapidly during the infusion to a lowv point that was less than 50% of control values. As the serum magnesium concentration declined after the discontinuation of the infusion, the serum iCT slowly increased, but was still below base-line levels 17 h after the end of the infusion, when the serum magnesium concentration was 3.8 mg/100 ml. In general, the changes in serum calcium paralleled the changes in serum iCT. Thus, the initial fall in serum iCT was accompanied by a fall in serum calcium and the rise in serum iCT that occurred after the infusion was accompanied by a rise in serum calcium.
No distinct pattern in serumi phosplhorus Nvas observed although there was a slight and transient decrease during the 1st h of the magnesium infusion. The serum iPTH remained undetectable throughout the period of study. Patient 3 (normocalcemic-normital detectable serumn iPTH). The effect of the infusion of 1,190 mg of magnesium as magnesium chloride over a 3-h period in patient 3 is seen in Fig. 2A . During the infusion period the serum iCT decreased rapidly and was accompanied by a fall in serum calcium, a rise in serum phosphorus, and a progressive decrease in serum iPTH to an undetectable level. Within an hour after the discontinuation of the infusion, when the serum magnesium was slowly returning toward baseline and the serum calcium was continuing to fall, the serum iPTH increased and subsequently reached base-line levels 2 h after discontinuation of the infusion.
The effect of the infusion of 480 mg of magnesium as magnesium sulfate over a 1-h period in patient 3 is shown in Fig. 2B . The pattern of response was similar to that produced by magnesium chloride ( Fig. 2A) (B) The effect of the infusion of 480 mg of magnesium as magnesium sulfate over a 1-h period on serum magnesium, iCT, calcium, phosphorus, and iPTH in patient 3.
The possibility that magnesium might blunt the response of medullary carcinoma cells to calcium stimuli was considered. To investigate this possibility, the effect of intravenous calcium administration on the depression of serum calcitonin produced by a magnesium load was studied in patient 3. The results are presented in Fig. 3 . 1,400 mg of magnesium as magnesium chloride was infused over a 4k-h period. During the last 11 h of the magnesium infusion 675 mg of calcium as calcium gluconate was also infused. The magnesium infusion resulted in the usual fall in serum iCT, but when calcium infusion was superimposed on the magnesium infusion to produce a rise of 2 mg/100 ml in serum calcium, there was almost a 10-fold increase in the serum iCT concentration. It should be noted that in this study the depression of serum iCT produced by hypermagnesemia was not accompanied by a detectable change in serum calcium, though a distinct increase in serum phosphorus was observed.
As part of the study depicted in Fig. 2A , the effect of magnesium infusion on the urinary excretion of magnesium, calcium, and phosphorus in patient 3 was investigated. 1,190 mg of magnesium as magnesium chloride was infused over a 3-h period. In the 3-h period following the infusion the urinary calcium and magnesium each increased by approximately 300%, while urinary phosphorus decreased to 50% of base-line values obtained 3 h before the infusion.
Serum protein concentrations remained relatively constant during all of the infusion studies with no consistent pattern of change.
Additional miagnesium infusion studies. The effect of magnesium infusion on circulating iCT was evaluated on three additional occasions in patient 2 and one additional occasion in patient 3. The results are summarized in Table I (4) found that the infusion of magnesium led to an increase in circulating iCT, which was accompanied by a fall in plasma calcium.
The reason for the disparity between our findings and the findings of in vitro, in situ, and in vivo studies in the normal pig is unknown. It is possible that the divergent responses are simply due to a species difference. However, it seems more likely that they reflect basic differences in metabolic or secretory characteristics of thyroid medullary carcinoma cells as compared to normal C cells. Although it is clear that magnesium administration caused a fall in serum iCT in our patients, it is uncertain if this was due to a direct action of magnesium on the synthesis or release of calcitonin, or whether the calcitonin-lowering effect was mediated through a secondary mechanism such as a fall in circulating calcium. In seven of the nine infusion studies reported in this paper, magnesium administration led to a decline in serum calcium. In six of the seven studies the fall in serum calcium paralleled the fall in serum iCT, while in one study the fall in serum calcium followed the fall in serum iCT (study 2a in Table I ). It has been demonstrated that lowering of the serum calcium level by EDTA administration leads to a decline in circulating iCT in patients with medullary carcinoma of the thyroid (8) . However, the minimal decrease in serum calcium required to reduce serum iCT in these patients has not been defined. It is possible that thyroid medullary carcinoma cells are extremely sensitive (more so than normal C cells) to small decrements in serum calcium which in some cases might go undetected with presently available methods.
Another possibility to account for our findings is that magnesium might in some way interfere with the response of medullary carcinoma cells to calcium. However, this did not appear to be the case; when calcium infusion was superimposed on magnesium infusion there was an almost 10-fold increase in serum iCT concentration (Fig. 3) . The calcium-induced increase in serum iCT was similar in magnitude to that reported by Melvin et al. (9) in a series of patients with overt medullary carcinoma of the thyroid. Nevertheless, the possibility that hypermagnesemia blunts the response of medullary carcinoma cells to physiologic levels of calcium, per- (4) observed that the response of intact pigs to magnesium clhloride infusioni was characterized by a rise in serum iCT and a fall in serum calcium, while magnesium infusion in a thyroparathyroidectomized pig led to a rise in serum calcium N-ith no detectable change in serum iCT. On the basis of these findings, the investigators suggested that the major factor responsible for the hypocalcemic effect of magnesium is calcitonin. This possibility is consistent w-ith previous reports which indicate that magniesitum administration lowers the serum calcium level in intact, but not thyroidectomized, cats and rats (10, 11) . In our studies of patients with medullary carcinoma the fall in serum calcium produced by the administration of magnesitum chloride or magnesium sulfate (observed in seven of nine studies) was accompanied by a fall, rather than a rise, in serum iCT. Therefore, the calcium-low-erinig effect produced by magnesium in these patients cannot be attributed to a calcitonin effect as was postulated in aniimlal studies.
The fall in serumil iPTH produced by magnesium administration in patient 3 is consistent with previously published observations that magnesium inhibits parathyroid hormone secretion (12, 13), except in certain patients with magnesium deficiency where magnesium may actually stimulate the release of parathyroid hormone (14, 15) . The fall in serumil calcium (Fig. 2) and in urine phosphorus in patient 3 could be secondary to the fall in serum iPTH produced by magnesium. However, in patient 2 with hvpercalcemia and bone metastases, a fall in serum calcium was observed in the presence of a consistently undetectable serum iPTH level.
Thus, in this patient the calcium-lowN-ering effect produced by magnesium caninot be attribtuted to either a rise in circulating iCT or a detectable fall in circulating iPTH. This observation suggests that the calciumlowering effect produced by mnagniesitunm is, in part at least, due to a redistribution of body calciumii that is not mediated through the actions of eitlher paratlhvroid hormone or calcitonin.
The hypocalcenmic effect produiced by magniesitum infusioIn could be related to the calcituric effect of magnlesitum (16, 1/7), which lhas been attributed to competitive inhiibition of tubular calciumni reabsorptioni. WVe observed a calciuric effect secondary to magniesitum infusion in patient 3, while urinary excretion studies were not carried out in the other two patielnts.
The chalnges in serumn phosplhortus levels induced by magnesium infusion in our patienits are of interest. In some of our studies the adminiistration of magnesium resuilted in a fall in serumni phosphorus while in other stuidies there wras either no change or a modest increase in serum phosplhorus. Analysis of our data indicates that the responise of sertlm plhosphorus appeared to be related to the anion that was infused with magnesium, ithl the low-ering of the serumi phosplhortus being associated N-ith sulfate inftusion. A hypophosphatemic effect of soditum sulfate has been previously noted and in one study wvas associated w-itlh a modest inicrease in turiniary phlosphate excretion (18. 19) .
Recently Gaut-vik and Tasljilan (20) Under basal conditions patient 1 lhad loose stools approximatelv every half lhour and marked borborvgmi. It is of interest that for several hours duiring and after magnesium infusion there was distinct abatement in these symptonms. It is possible that this improvement w-as related to the fall in circulating calcitonin since it lhas been suiggested that the diarrhea occurring in association wvith medullarv carcinoma of the thyvroid may be due to calcitonin inhlibition of sodium cand water absorption bv the intestine (21) . On the otlher hand, hligh contenits of serotonin and( prostaglandins lhav e been fotund in some thyroid medullarv carcinomas and both of these compounds are knoxvni to stimulate smooth muscle (22) (23) (24) . The possibility that, in addition to its effect on calcitonin, magniesiumil might influence the secretion or sy-nthesis of other bioactive substances produced by tllhroid medullary carcinomas, including prostaglandi ns, serotonin, ACTH, and histaminase, is currently tunder investigationi.
